APA Citatie

Namatame, C., Misu, T., Takai, Y., Nishiyama, S., Nakashima, I., Fujihara, K., & Aoki, M. (2021). CH50 as a putative biomarker of eculizumab treatment in neuromyelitis optica spectrum disorder. Heliyon.

Chicago Style citaat

Namatame, Chihiro, Tatsuro Misu, Yoshiki Takai, Shuhei Nishiyama, Ichiro Nakashima, Kazuo Fujihara, en Masashi Aoki. "CH50 As a Putative Biomarker of Eculizumab Treatment in Neuromyelitis Optica Spectrum Disorder." Heliyon 2021.

MLA citatie

Namatame, Chihiro, et al. "CH50 As a Putative Biomarker of Eculizumab Treatment in Neuromyelitis Optica Spectrum Disorder." Heliyon 2021.